SPDR S&P Pharmaceuticals ETF
XPH
XPH
67 hedge funds and large institutions have $109M invested in SPDR S&P Pharmaceuticals ETF in 2020 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 12 increasing their positions, 23 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less ownership
Funds ownership: →
48% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 23
51% less capital invested
Capital invested by funds: $224M → $109M (-$115M)
Holders
67
Holding in Top 10
–
Calls
$3.57M
Puts
$204K
Top Buyers
| 1 | +$21.2M | |
| 2 | +$16.9M | |
| 3 | +$2.73M | |
| 4 |
BCM
Brookstone Capital Management
Wheaton,
Illinois
|
+$2.46M |
| 5 |
SCA
Snowden Capital Advisors
New York
|
+$709K |
Top Sellers
| 1 | -$56.5M | |
| 2 | -$38.8M | |
| 3 | -$19.4M | |
| 4 |
Goldman Sachs
New York
|
-$8.89M |
| 5 |
Barclays
London,
United Kingdom
|
-$1.89M |